Health System Cuts Unnecessary Blood Thinner Prescriptions by Targeting Overuse
A VA health system reduced risky antiplatelet overprescribing in DOAC patients using clinician education and smart electronic alerts.
Summary
Overprescribing antiplatelet drugs alongside blood thinners (DOACs) is a widespread problem that raises bleeding risk. A quality improvement study across seven Veterans Health Administration sites tested a two-part fix: clinician education followed by electronic alerts routed to clinical pharmacists. Over 25 months, antiplatelet prescribing dropped from 26.1% to 17.9% at intervention sites, compared to a smaller drop at control sites. The biggest gains were in patients with stable coronary artery disease, where guidelines already recommend stopping antiplatelet therapy. Researchers estimate this approach could prevent roughly 40 major bleeding events annually across 20,000 eligible VHA patients — a meaningful, scalable win for reducing medication-related harm.
Detailed Summary
Unnecessary combination drug therapy is one of medicine's persistent blind spots. When patients on direct oral anticoagulants (DOACs) are also prescribed antiplatelet medications without a clear indication, their bleeding risk rises substantially — yet overprescribing remains common across health systems. A new quality improvement study published in JAMA Internal Medicine offers a practical, scalable model for fixing this.
Researchers from the Veterans Health Administration tested a multilevel antithrombotic stewardship intervention across seven health systems in Florida, Georgia, Puerto Rico, and the U.S. Virgin Islands. The approach combined initial clinician education with a later-added electronic flag embedded in a DOAC population management tool — crucially, the alert was routed to clinical pharmacists rather than physicians, reducing alert fatigue and workflow disruption.
The results were significant. Antiplatelet prescribing fell from 26.1% to 17.9% at intervention sites over 25 months, versus a drop from 30.1% to 21.6% at control sites — a meaningful difference of 0.58 percentage points per six-month period. Patients with stable coronary artery disease saw the greatest benefit, a population where current guidelines already support stopping antiplatelet therapy when a DOAC is in use.
The clinical math is compelling. Based on meta-analyses of randomized trials, for every 12 patients successfully taken off unnecessary antiplatelet therapy, one major or clinically relevant bleeding event is prevented. Extrapolated across 20,000 eligible VHA patients, this intervention could prevent approximately 40 serious bleeds annually.
Caveats apply. This was a quality improvement study, not a randomized controlled trial, limiting causal certainty. Results come from a single integrated health system (the VHA), which may not generalize to private or fragmented care settings. Still, the low-disruption design and measurable outcomes make this a promising model for broader antithrombotic stewardship programs.
Key Findings
- Antiplatelet prescribing dropped from 26.1% to 17.9% over 25 months at intervention sites vs. smaller control-site reductions.
- Routing electronic alerts to pharmacists rather than doctors reduced burden while maintaining effectiveness.
- Every 12 patients successfully de-prescribed antiplatelet therapy prevents one major bleeding event.
- Stable coronary artery disease patients benefited most, aligning with current guideline recommendations.
- Extrapolated estimates suggest ~40 major bleeds prevented annually across 20,000 eligible VHA patients.
Methodology
This is a news report summarizing a quality improvement study published in JAMA Internal Medicine, a high-credibility peer-reviewed journal. The study used an interrupted time-series-style multilevel design across seven VHA sites with contemporaneous control sites, providing moderate-strength evidence. It is not a randomized controlled trial, so causality cannot be definitively established.
Study Limitations
As a quality improvement study rather than an RCT, the findings carry inherent confounding risk and cannot confirm causation. Results are drawn exclusively from the VHA, a uniquely integrated system, and may not translate to community or private healthcare settings. Longer-term outcomes such as sustained prescribing changes or cardiovascular event rates were not reported in this summary.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: